Asthma Clinical Trial
— CAPSOfficial title:
Childhood Asthma Perception Study
Verified date | February 2023 |
Source | Albert Einstein College of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized controlled trial will include Latino and Black adolescents with asthma ages 10-17 years old and their caregivers. Participants will be recruited from clinics in the Bronx, New York. The primary aims are to examine the efficacy of peak expiratory flow (PEF) prediction with feedback versus control feedback on 1) under-perception of asthma symptoms 2) controller medication adherence and 3) asthma control and emergency health care use. These aims will be examined across a 1-year follow-up. An exploratory aim examines the hypothesized pathway that the PEF intervention reduces under-perception of symptoms, shifts illness representations toward the professional model and increases adolescents' and parents' asthma management self-efficacy, resulting in greater medication adherence and improved asthma control.
Status | Completed |
Enrollment | 363 |
Est. completion date | July 28, 2022 |
Est. primary completion date | July 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 17 Years |
Eligibility | Inclusion Criteria: - 10-17 years of age - Diagnosis of asthma (in medical record) - Report of breathing problems within the past 12 months - Prescribed a controller medication for asthma - At least one parent self-identifies as Latino or Black - The participating parent has primary or at least equal responsibility for the adolescent Exclusion Criteria: - Cognitive learning disability (parent report) - No prescription for asthma controller medication - Inability to perform acceptable PEF blows - Race/ethnicity other than Latino or Black - Other significant pulmonary conditions (cystic fibrosis) |
Country | Name | City | State |
---|---|---|---|
United States | Jacobi Medical Center | Bronx | New York |
United States | Montefiore Medical Center | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Albert Einstein College of Medicine | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Asthma Symptom Perception with Asthma Monitor (AM2) as percentage of guesses in the Under-Perception zone | The percentage of times a child under-perceives the severity of asthma symptoms | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Asthma Illness Representation Scale (AIRS) | 37-item scale measuring risk factors for the underutilization of controller medications | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Asthma Management Self-Efficacy (ASE) scale: Parent and child versions | 13-item scale measures parent's confidence in their ability to help manage child's asthma | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Pediatric Asthma Quality of Life Questionnaire (PAQLQ) | 23-item self report questionnaire assessing child's overall functioning in relation to asthma | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Medication Adherence - percentage of total doses taken per day/prescribed per day | Self report of daily medication use, in relation to the prescribed use | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Health Care Use - Electronic Medical Record (EMR) review of asthma-related Emergency Department visits and hospitalizations | Quantity of asthma-related emergency visits throughout the duration of the study | Change from Pre-intervention to 12-month-follow-up (15 months) | |
Secondary | Asthma Control Test (C-ACT) | Self-report questionnaire for adolescents and parents | Change from Pre-intervention to 12-month-follow-up (15 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|